Opportunities of drugs based on D-mannose and herbal components in the treatment and prevention of recurrent lower urinary tract infections in women

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Recurrent cystitis is a common form of urinary tract infections. In the treatment of this disease antibacterial drugs are usually used. At the same time, there are plant components that can be a worthy substitute for antibiotic therapy.

AIM: To evaluate the efficacy and safety of the biologically active complex Cystalis, containing D-mannose, grape seed extract and bearberry extract, in the treatment and prevention of recurrent cystitis in women.

MATERIALS AND METHODS: The study included 60 women with recurrent cystitis. All patients answered the Acute Cystitis Symptom Scale (ACSS). The patients were divided into 2 groups of 30 people each. Patients of the 1st group received standard antibiotic therapy for recurrence of cystitis in accordance with the results of bacteriological examination of urine, followed by observation for 6 months. Patients of the second group instead of antibiotic therapy received the biologically active complex Cistalis one capsule (350 mg) 2 times a day for 3 months, followed by observation for 3 months.

RESULTS: Before the start of treatment Escherichia coli was detected in 26 patients (86.7%) in the 1st group and in 28 (93.3%) patients in the 2nd group. At a follow-up visit 30 days after the initial examination the total score on the ACSS scale in patients of the 1st group decreased from 6.6 ± 1.4 to 0.03 ± 0.18 points (p < 0.001), in patients of the 2nd group – from 6.4 ± 1.3 to 0 (p < 0.001). The sum of scores in the Quality of Life (QoL) domain in the representatives of the 1st group decreased from 6.3 ± 1.3 to 0 (p < 0.001), and in the 2nd group decresead from 5.6 ± 1.0 also to 0 (p < 0.001). In patients of both groups, the level of leukocytes and erythrocytes in the urine significantly decreased. During the 6-month follow-up period 8 recurrences of UTIs were registered in patients of the 1st group, and only 2 recurrences in patients of the 2nd group. The probability of developing a recurrence of cystitis in patients of the 2nd group was significantly lower than in patients of the 1st group (χ2 = 4.603, p = 0.032).

CONCLUSIONS: An analysis of the results of the study showed the high efficiency of using the Cystalis complex for the treatment of cystitis and the prevention of its recurrence.

About the authors

Igor S. Shormanov

Yaroslavl State Medical University

Email: i-s-shormanov@yandex.ru
ORCID iD: 0000-0002-2062-0421
SPIN-code: 7772-8420
Scopus Author ID: 6507085029

Dr. Sci. (Med.), Professor, Head of the Department of Urology with Nephrology

Russian Federation, Yaroslavl

Andrey S. Solovyov

Yaroslavl State Medical University

Email: a-s-soloviev89@yandex.ru
ORCID iD: 0000-0001-5612-3227
SPIN-code: 8198-2122

Сand. Sci. (Med), Assistant of the Department of Urology with Nephrology

Russian Federation, Yaroslavl

Ivan A. Chirkov

Yaroslavl State Medical University

Email: kafuro@mail.ru

Clinical resident, Department of Urology with Nephrology

Russian Federation, Yaroslavl

Dmitry N. Shchedrov

Regional Pediatric Clinical Hospital

Email: shedrov.dmitry@yandex.ru
ORCID iD: 0000-0002-0686-0445
SPIN-code: 7354-7379

Doc. Sci. (Med.), Head of the Pediatric Urology and Andrology Unit

Russian Federation, Yaroslavl

Stepan S. Krasnyak

Research Institute of Urology and Interventional Radiology after named N.A. Lopatkin – branch of the National Medical Research Center of Radiology

Email: krasnyakss@mail.ru
ORCID iD: 0000-0001-9819-6299
SPIN-code: 2627-2783
Scopus Author ID: 57223324703

Cand. Sci. (Med.), Associate Researcher of the Department of Andrology and Human Reproduction

Russian Federation, 51, 3-ya Parkovaya st., Moscow, 105425

Igor A. Shaderkin

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: info@uroweb.ru
ORCID iD: 0000-0001-8669-2674
SPIN-code: 3840-1697

Cand. Sci. (Med.), Head of the Health Laboratory of the Institute of Digital Medicine

Russian Federation, 51, 3-ya Parkovaya st., Moscow, 105425

References

  1. Laupland KB, Ross T, Pitout JDD, et al. Community-onset urinary tract infections: A population-based assessment. Infection. 2007;35:150. doi: 10.1007/s15010-007-6180-2
  2. Ikäheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: Analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996;22(1):91–99. doi: 10.1093/clinids/22.1.91
  3. Borisov VV. Diagnosis and theraphy of urinary infections. What should always remember (clinical lecture). Part 1. Urologicheskie vedomosti. 2017;7(3):52–59. (In Russ.) doi: 10.17816/uroved7352-59
  4. Apolikhina IA, Teterina TA. Diagnostika i lechenie tsistita u zhenshchin reproduktivnogo vozrasta. Obstetrics and Gynecology. 2019;(6S):26–29. (In Russ.)
  5. Rafalsky VV, Moiseeva EM. Epidemiology of uncomplicated outpatient urinary tract infections in the Russian Federation. Vestnik Urologii. 2018;6(2):30–37. (In Russ.) doi: 10.21886/2308-6424-2018-6-2-30-37
  6. Bouckaert J, Berglund J, Schembri M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesion. Mol Microbiol. 2005;55(2):441–455. doi: 10.1111/j.1365-2958.2004.04415.x
  7. King SS, Young DA, Nequin LG, Carnevale EM. Use of specific sugars to inhibit bacterial adherence to equine endometrium in vitro. Am J Vet Res. 2000;61(4):446–449. doi: 10.2460/ajvr.2000.61.446
  8. Krasnyak SS. Non-antibacterial therapy and prevention of acute and recurrent cystitis: existing options and future trends. Experimental and clinical urology. 2020;(1):136–143. (In Russ.) doi: 10.29188/2222-8543-2020-12-1-136-143
  9. Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: A randomized clinical trial. World J Urol. 2014;32:79–84. doi: 10.1007/s00345-013-1091-6
  10. Porru D, Parmigiani A, Tinelli C, et al. Oral D-mannose in recurrent urinary tract infections in women: A pilot study. J Clin Urol. 2014;7(3):208–213. doi: 10.1177/2051415813518332
  11. Domenici L, Monti M, Bracchi C, et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci. 2016;20(13):2920–2925.
  12. Howell AB. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Mol Nutr Food Res. 2007;51(6):732–737. doi: 10.1002/mnfr.200700038
  13. Li WG, Zhang XY, Wu YJ, Tian X. Anti-inflammatory effect and mechanism of proanthocyanidins from grape seeds. Acta Pharmacol Sin. 2001;22(12):1117–1120.
  14. Chang WC, Hsu FL. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostaglandins, Leukot Essent Fat Acids. 1989;38(3):181–188. doi: 10.1016/0952-3278(89)90070-7
  15. Quintus J, Kovar K-A, Link P, Hamacher H. Urinary excretion of arbutin metabolites after oral administration of bearberry leaf extracts. Planta Med. 2005;71(2):147–152. doi: 10.1055/s-2005-837782
  16. Geetha RV, Roy A, Lakshmi T. Nature’s weapon against urinary tract infections. Int J Drug Dev Res. 2011;3(3):85–100.
  17. Rotblatt M. Herbal Medicine: Expanded Commission E Monographs. Ann Intern Med. 2013;133(6):487. doi: 10.7326/0003-4819-133-6-200009190-00031
  18. Lenger SM, Bradley MS, Thomas DA, et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;223(2):265.e1–265.e13. doi: 10.1016/j.ajog.2020.05.048
  19. Сommittee on herbal medicinal products (HMPC). Assessment report on Arctostaphylos uva-ursi (L.) Spreng., folium. European Medicines Agency, 2012. P. 1–34.
  20. Schindler G, Patzak U, Brinkhaus B, et al. Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae ursi extract as film-coated tablets and aqueous solution in healthy humans. J Clin Pharmacol. 2002;42(8):920-927. doi: 10.1177/009127002401102740
  21. Maris P. Modes of action of disinfectants. Rev Sci Tech. 1995;14(1):47–55. doi: 10.20506/rst.14.1.829
  22. Voloboi NL, Butakova LYu, Smirnov IV. Study of antimicrobial arbutin and hydroquinone in certain gram – flora of representatives. Khimija rastitel’nogo syr’ja. 2013;(1):179–182. (In Russ.) doi: 10.14258/jcprm.1301179
  23. Jepson R, Craig J, Williams G. Cranberry products and prevention of urinary tract infections. JAMA. 2013;310(13):1395–1396. doi: 10.1001/jama.2013.277509
  24. Cranberry (Vaccinii macrocarpi fructus). ESCOP Monographs: The scientific foundation for herbal medicinal products. NY: ESCOP (Exeter), Georg Thieme Verlarg (Stuttgart), Thieme New York, 2009. P. 255–269.
  25. Scientific Opinion on the substantiation of a health claim related to CranMax® and reduction of the risk of urinary tract infection by inhibiting the adhesion of certain bacteria in the urinary tract pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J. 2016;12(5):3657–3668.
  26. Beecher GR. Proanthocyanidins: Biological activities associated with human health. Pharm Biol. 2004;42(1):2–20. doi: 10.3109/13880200490893474
  27. Platonov VV, Hadarcev AA, Belyaeva EA. Sweet sawberry (comarum palustre l.) In medical practice (literature review). Clinical Medicine and Pharmacology. 2019;5(4):66–70. (In Russ.) doi: 10.12737/2409-3750-2020-5-4-66-70
  28. Blazsó G, Gábor M, Rohdewald P. Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie. 1997;52(5):380–382.
  29. Vadekeetil A, Alexandar V, Chhibber S, Harjai K. Adjuvant effect of cranberry proanthocyanidin active fraction on antivirulent property of ciprofloxacin against Pseudomonas aeruginosa. Microb Pathog. 2016;90:98–103. doi: 10.1016/j.micpath.2015.11.024

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. Kaplan–Meier relapse-free survival curve in patients of the 1st and 2nd groups during the 6-month follow-up period

Download (138KB)
Indexing metadata

Copyright (c) 2022 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies